Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q2 2017 · 10-Q
Revenue$33.75M$33.75M+1.2% vs Q2 2016 Net Income-$30.76M-$30.76MN/M vs Q2 2016 EPS Diluted-$230.00-$230.00N/M vs Q2 2016 Gross Profit$4,992,000−7.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flowderived-$16,996,000N/M Free Cash Flowderived-$17,226,000N/M Margins · derivedGross margin14.8%−1.4 pt vs Q2 2016
Operating margin-75.5%−10.3 pt vs Q2 2016
Net margin-91.1%−10.5 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 8, 2017 · 39 d after period end